Website intended for a NZ health professional readership
We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 8 May.
Consultant cardiologist Chris Ellis looks at the management of short runs of atrial fibrillation detected by pacemaker
1. Healey JS, Lopes RD, Granger CB, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med 2024;390(2):107–17.
2. Glotzer TV, Daoud EG, Wyse DG, et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2(5):474–80.
3. Van Gelder IC, Healey JS, Crijns HJGM, et al. Duration of devicedetected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017;38(17):1339–44.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
